These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

670 related items for PubMed ID: 21425995

  • 1. Inhibitors of MDM2 and MDMX: a structural perspective.
    Riedinger C, McDonnell JM.
    Future Med Chem; 2009 Sep; 1(6):1075-94. PubMed ID: 21425995
    [Abstract] [Full Text] [Related]

  • 2. Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction.
    Lemos A, Leão M, Soares J, Palmeira A, Pinto M, Saraiva L, Sousa ME.
    Med Res Rev; 2016 Sep; 36(5):789-844. PubMed ID: 27302609
    [Abstract] [Full Text] [Related]

  • 3. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX.
    Hu B, Gilkes DM, Chen J.
    Cancer Res; 2007 Sep 15; 67(18):8810-7. PubMed ID: 17875722
    [Abstract] [Full Text] [Related]

  • 4. Efficient reactivation of p53 in cancer cells by a dual MdmX/Mdm2 inhibitor.
    Qin L, Yang F, Zhou C, Chen Y, Zhang H, Su Z.
    J Am Chem Soc; 2014 Dec 31; 136(52):18023-33. PubMed ID: 25453499
    [Abstract] [Full Text] [Related]

  • 5. Affinity-based screening of MDM2/MDMX-p53 interaction inhibitors by chemical array: identification of novel peptidic inhibitors.
    Noguchi T, Oishi S, Honda K, Kondoh Y, Saito T, Kubo T, Kaneda M, Ohno H, Osada H, Fujii N.
    Bioorg Med Chem Lett; 2013 Jul 01; 23(13):3802-5. PubMed ID: 23726030
    [Abstract] [Full Text] [Related]

  • 6. Molecular basis for the inhibition of p53 by Mdmx.
    Popowicz GM, Czarna A, Rothweiler U, Szwagierczak A, Krajewski M, Weber L, Holak TA.
    Cell Cycle; 2007 Oct 01; 6(19):2386-92. PubMed ID: 17938582
    [Abstract] [Full Text] [Related]

  • 7. Small molecule inhibitors of the p53-MDM2.
    Hu CQ, Hu YZ.
    Curr Med Chem; 2008 Oct 01; 15(17):1720-30. PubMed ID: 18673221
    [Abstract] [Full Text] [Related]

  • 8. A Unique Mdm2-Binding Mode of the 3-Pyrrolin-2-one- and 2-Furanone-Based Antagonists of the p53-Mdm2 Interaction.
    Surmiak E, Twarda-Clapa A, Zak KM, Musielak B, Tomala MD, Kubica K, Grudnik P, Madej M, Jablonski M, Potempa J, Kalinowska-Tluscik J, Dömling A, Dubin G, Holak TA.
    ACS Chem Biol; 2016 Dec 16; 11(12):3310-3318. PubMed ID: 27709883
    [Abstract] [Full Text] [Related]

  • 9. Systematic mutational analysis of peptide inhibition of the p53-MDM2/MDMX interactions.
    Li C, Pazgier M, Li C, Yuan W, Liu M, Wei G, Lu WY, Lu W.
    J Mol Biol; 2010 Apr 30; 398(2):200-13. PubMed ID: 20226197
    [Abstract] [Full Text] [Related]

  • 10. Structure-based design of high affinity peptides inhibiting the interaction of p53 with MDM2 and MDMX.
    Phan J, Li Z, Kasprzak A, Li B, Sebti S, Guida W, Schönbrunn E, Chen J.
    J Biol Chem; 2010 Jan 15; 285(3):2174-83. PubMed ID: 19910468
    [Abstract] [Full Text] [Related]

  • 11. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.
    Soares J, Espadinha M, Raimundo L, Ramos H, Gomes AS, Gomes S, Loureiro JB, Inga A, Reis F, Gomes C, Santos MMM, Saraiva L.
    Mol Oncol; 2017 Jun 15; 11(6):612-627. PubMed ID: 28296148
    [Abstract] [Full Text] [Related]

  • 12. Targeting the conformational transitions of MDM2 and MDMX: insights into dissimilarities and similarities of p53 recognition.
    Macchiarulo A, Giacchè N, Carotti A, Baroni M, Cruciani G, Pellicciari R.
    J Chem Inf Model; 2008 Oct 15; 48(10):1999-2009. PubMed ID: 18826207
    [Abstract] [Full Text] [Related]

  • 13. MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.
    Tisato V, Voltan R, Gonelli A, Secchiero P, Zauli G.
    J Hematol Oncol; 2017 Jul 03; 10(1):133. PubMed ID: 28673313
    [Abstract] [Full Text] [Related]

  • 14. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment.
    Zhao Y, Aguilar A, Bernard D, Wang S.
    J Med Chem; 2015 Feb 12; 58(3):1038-52. PubMed ID: 25396320
    [Abstract] [Full Text] [Related]

  • 15. Targeting the conformational transitions of MDM2 and MDMX: insights into key residues affecting p53 recognition.
    Carotti A, Macchiarulo A, Giacchè N, Pellicciari R.
    Proteins; 2009 Nov 15; 77(3):524-35. PubMed ID: 19507240
    [Abstract] [Full Text] [Related]

  • 16. Monitoring Ligand-Induced Protein Ordering in Drug Discovery.
    Grace CR, Ban D, Min J, Mayasundari A, Min L, Finch KE, Griffiths L, Bharatham N, Bashford D, Kiplin Guy R, Dyer MA, Kriwacki RW.
    J Mol Biol; 2016 Mar 27; 428(6):1290-1303. PubMed ID: 26812210
    [Abstract] [Full Text] [Related]

  • 17. Molecular interaction fields and 3D-QSAR studies of p53-MDM2 inhibitors suggest additional features of ligand-target interaction.
    Dezi C, Carotti A, Magnani M, Baroni M, Padova A, Cruciani G, Macchiarulo A, Pellicciari R.
    J Chem Inf Model; 2010 Aug 23; 50(8):1451-65. PubMed ID: 20726601
    [Abstract] [Full Text] [Related]

  • 18. Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX.
    Pazgier M, Liu M, Zou G, Yuan W, Li C, Li C, Li J, Monbo J, Zella D, Tarasov SG, Lu W.
    Proc Natl Acad Sci U S A; 2009 Mar 24; 106(12):4665-70. PubMed ID: 19255450
    [Abstract] [Full Text] [Related]

  • 19. Small-molecule MDM2-p53 inhibitors: recent advances.
    Zhang B, Golding BT, Hardcastle IR.
    Future Med Chem; 2015 Mar 24; 7(5):631-45. PubMed ID: 25921402
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.